The research team, led by Fa-Qiang Zhang and colleagues at Lanzhou University in collaboration with clinicians in Zhengzhou and Lanzhou, China, systematically searched PubMed, the Cochrane Library, Web of Science, and Embase from database inception through August 1, 2026. Their protocol was registered in advance in PROSPERO, and they applied the Cochrane risk-of-bias tool to each randomized controlled trial they found. In total, sixteen randomized controlled trials encompassing 820 children and adolescents met the inclusion criteria, spanning interventions as diverse as biofeedback, relaxation training, cognitive behavioral therapy, therapist-led group training, headache education, a self-guided CD-ROM program called Headstrong, music therapy, hypnotherapy, and meditation.

What makes this analysis methodologically interesting is its use of network meta-analysis, a statistical framework that goes beyond the traditional pairwise comparison of two treatments. In a standard meta-analysis, only trials that directly compare the same two interventions can be pooled. Network meta-analysis instead builds a connected web of evidence, allowing treatments that were never tested against each other in a single trial to be compared indirectly through their shared comparators—in this case, often a waiting list control group. The team used Stata 17 to generate network diagrams, league tables, and surface under the cumulative ranking curve (SUCRA) values, a metric that expresses the probability that each treatment ranks highest for a given outcome.

The headline finding concerns headache frequency, the outcome most families and clinicians care about when considering preventive therapy. Compared with waiting list controls, biofeedback produced a standardized mean difference of −1.11 (95% confidence interval −2.04 to −0.17), therapist-assisted relaxation yielded −1.06 (95% CI −2.04 to −0.07), and relaxation training alone achieved −0.69 (95% CI −1.21 to −0.17), all indicating meaningful reductions in how frequently headaches occurred. Biofeedback topped the frequency ranking with a SUCRA value of 81.4%, meaning that across the simulated ranking distribution it had the highest probability of being the most effective intervention for cutting down headache days.

Biofeedback itself deserves a technical explanation, because its prominence in these results is not accidental. The technique teaches children to gain voluntary control over physiological processes normally considered automatic—skin temperature, muscle tension in the scalp and neck, or blood flow patterns—by displaying those signals in real time on a monitor. A child watching a thermometer trace rise as they relax learns, through repeated feedback loops, to reproduce the physiological state associated with reduced headache activity. Pediatric trials of this approach stretch back decades, including early autogenic feedback studies from the 1980s and 1990s, and the new network analysis is consistent with an earlier pediatric meta-analysis published in Pediatrics in 2016 that found biofeedback to be a promising prophylactic for childhood migraine.

On headache duration, the most striking result came from an unexpected quarter: the Headstrong CD-ROM, a structured, self-administered behavioral program, achieved a standardized mean difference of −1.63 (95% CI −2.95 to −0.30) against waiting list, the largest effect size recorded anywhere in the analysis, with a SUCRA ranking of 80.5%. Combined biofeedback-plus-relaxation training followed closely at −1.54 (95% CI −2.95 to −0.13), while relaxation alone shortened headache episodes at −0.91 (95% CI −1.61 to −0.21). The strong showing of a digital, self-guided format is notable because it hints that scalable, low-cost delivery—no therapist required, no waiting room, no travel—may be able to deliver benefits comparable to hands-on care, a proposition with obvious appeal for stretched pediatric services.

For headache intensity, the field widened considerably. Education about headaches alone produced a standardized mean difference of −0.96 (95% CI −1.72 to −0.19) and claimed the top intensity ranking with a SUCRA of 75.7%. Biofeedback (−0.85), therapist-administered group training (−0.78), cognitive behavioral therapy (−0.76), and relaxation (−0.63) all showed statistically significant improvements over control as well. That simple structured education—teaching children and parents what a primary headache is, what triggers it, and how to respond—could rank so highly is one of the more provocative implications of the study, though the authors are careful to frame these rankings as relative probabilities rather than proof of definitive clinical superiority.

The authors are equally candid about the limitations, and their caution is warranted. The certainty of evidence, assessed with the Confidence in Network Meta-Analysis (CINeMA) framework, was rated as very low across most comparisons, and many effect estimates were imprecise, with confidence intervals wide enough to accommodate both clinically trivial and substantially beneficial effects. Sixteen trials and 820 participants is a modest evidence base from which to rank more than a dozen interventions, and the underlying trials varied in age—some dating to the 1980s—in diagnostic criteria, outcome measurement, and comparator choice. Standardized mean differences, while necessary when studies use different scales, are harder to translate into the language parents actually want: how many fewer headache days per month, or how many minutes shorter an episode will be.

Context matters for interpreting why this work matters now. Epidemiological reviews have established that primary headaches affect a substantial proportion of school-age children and adolescents worldwide, and studies cited by the authors link pediatric headache to reduced school performance, degraded quality of life, and elevated rates of anxiety and depressive symptoms. Yet pharmacological preventives approved and tested specifically for children remain limited, and behavioral therapies have historically been recommended on the basis of evidence too fragmented to say which one a clinician should try first. Previous network meta-analyses in adults and one earlier pediatric analysis in Pediatrics had begun to organize this landscape, but the new World Journal of Pediatrics review extends it with more recent trials and a formal certainty assessment.

The practical takeaway is a nuanced one. For a child whose primary problem is frequent headaches, the analysis points toward biofeedback and therapist-assisted relaxation as the best-supported behavioral options. For a child whose episodes are long and disruptive, self-guided digital programs such as Headstrong or combined biofeedback-relaxation protocols deserve consideration, with the caveat that the evidence base is thin and the CD-ROM format itself feels like a relic of an earlier digital era—its modern successors, internet-delivered cognitive behavioral programs, are represented in the trial pool but did not dominate the rankings. For children whose main complaint is pain intensity, even structured education may deliver measurable relief. None of these findings should be read as a green light to abandon medical evaluation; the authors themselves describe their conclusions as exploratory. What the analysis does establish is that the question of drug-free headache care in children is now answerable in comparative, quantitative terms—and that the answer, pending better trials, leans encouragingly toward the behavioral side of the clinic.

Subject of Research: Comparative efficacy of non-pharmacological interventions for pediatric primary headaches

Article Title: Efficacy of non-pharmacological interventions for pediatric primary headaches: a systematic review and network meta-analysis

Article References: Zhang, F.-Q., Wu, Y.-N., Liu, W.-D., Yang, K.-H., Li, X.-X., & Wang, S.-Y. (2026). Efficacy of non-pharmacological interventions for pediatric primary headaches: a systematic review and network meta-analysis. World Journal of Pediatrics. https://doi.org/10.1007/s12519-026-01103-9

Image Credits: AI Generated

DOI: 10.1007/s12519-026-01103-9

Keywords: pediatric headache, migraine, tension-type headache, biofeedback, relaxation training, cognitive behavioral therapy, network meta-analysis, non-pharmacological interventions, children, adolescents, Headstrong CD-ROM, evidence certainty

The research team, based at Ludwig-Maximilians-University Munich, took their laboratory into the field, following healthy volunteers on a five-day expedition through the Italian Alps in August 2022. Rather than simulating altitude in a hypoxic chamber, the investigators measured participants under genuine expedition conditions, ascending from the valley town of Varallo at 450 meters to the Capanna Regina Margherita at 4554 meters, one of the highest permanently staffed buildings in Europe. At each stage of the climb, participants completed structured headache questionnaires, rated their pain on a numerical scale from zero to ten, filled in the 2018 Lake Louise Acute Mountain Sickness Score, and provided samples of tear fluid for neuropeptide analysis. Certified mountain guides from the International Federation of Mountain Guides Association accompanied every group, and the protocol was approved by the university ethics committee.

The choice of tear fluid as the sampling medium is one of the study’s most intriguing technical features. Collecting blood at 4554 meters is cumbersome, and obtaining cerebrospinal fluid is out of the question in a field setting. Tear fluid, by contrast, can be aspirated from the lateral corner of each eye with a thin plastic capillary in under a minute, provided the investigator avoids irritating the ocular surface and triggering reflex tearing, which would dilute the sample. The researchers collected fluid from both eyes, pooled it after confirming no significant left-right differences at baseline, stabilized it in protein extraction reagent, kept it on dry ice, and later quantified CGRP concentrations with a commercial enzyme-linked immunosorbent assay read in duplicate on a spectrometer. The approach offers a noninvasive window into a neuropeptide that is otherwise difficult to track outside a hospital laboratory.

CGRP itself is a potent vasodilatory neuropeptide released from the endings of the trigeminovascular system, the network of sensory nerves that innervates the blood vessels of the brain’s protective membranes. Decades of work have established it as a central player in migraine: levels rise during spontaneous attacks, injecting CGRP can provoke migraine-like headaches in susceptible patients, and drugs that block the molecule or its receptor have transformed migraine prevention in recent years. Because high-altitude headache shares clinical features with migraine, including aggravation by physical activity, and because a history of migraine is a known risk factor for altitude headache, the Munich team hypothesized that hypobaric hypoxia might activate the same trigeminovascular pathway and drive CGRP release at altitude.

The expedition data gave that hypothesis substantial support. Of the 24 originally recruited participants, 13 completed the full protocol with usable tear samples, a reduction the authors attribute to early terminations and insufficient fluid volumes. Among these 13, headache burden climbed steadily with altitude. No one reported headache at baseline in the valley, but 46 percent did so after reaching 3498 meters on day two, 62 percent at 3647 meters on day three, and a striking 85 percent at 4554 meters on day four, when the mean pain score reached 3.2 on the ten-point scale. Eight participants, or 62 percent, fulfilled the formal ICHD-3 criteria for high-altitude headache at the highest hut, a figure consistent with the 36 to 73 percent incidence reported in earlier studies at comparable elevations.

The CGRP measurements revealed a pattern that was invisible in the group average. Across all participants, tear fluid CGRP levels at 4554 meters were not significantly different from baseline values, a result that on its own might have suggested the neuropeptide was irrelevant. But when the researchers split the cohort by symptom severity, a clear signal emerged. The six participants who developed moderate-to-severe headaches, with mean pain scores of 5.0, showed a substantial rise in tear fluid CGRP, averaging an increase of 1.86 nanograms per milliliter from baseline, while the seven participants with only mild headaches actually showed a slight decrease of 0.19 nanograms per milliliter. The difference between the groups was statistically significant, and baseline CGRP levels had been virtually identical, indicating that the elevation was triggered by the altitude exposure itself rather than reflecting a pre-existing trait.

The same dissociation appeared when participants were classified by diagnosis. Those meeting ICHD-3 criteria for high-altitude headache showed a mean CGRP increase of 1.49 nanograms per milliliter, compared with a decrease of 0.42 in those without the diagnosis. Even more striking, six participants, nearly half the cohort, developed a headache that met criteria for migraine without aura, complete with moderate-to-severe pulsating pain, nausea or vomiting in half of cases, and photophobia in some. These migraine-like sufferers reported higher pain intensity and a significantly larger CGRP rise of 1.75 nanograms per milliliter than their symptom-free counterparts. Notably, oxygen saturation, which hovered around 78 percent at the highest altitude for everyone, did not differ between headache and non-headache groups, suggesting that the degree of hypoxia alone did not determine who suffered.

The cerebral circulation told a quieter story. Using transcranial color-coded duplex sonography at baseline and at 4554 meters, the team measured blood flow velocity in the middle cerebral arteries on both sides, calculating mean flow velocities and the Lindegaard index to screen for vasospasm. Neither the presence of high-altitude headache nor of migraine-like symptoms was associated with differences in flow velocity or in the change from baseline, and there was no evidence of vasospasm in any group. This absence of a vascular signature is itself informative: it shifts attention away from simple blood-vessel constriction or dilation as the cause of altitude pain and toward neurogenic inflammation, the process by which activated trigeminal nerves release CGRP and other mediators directly around meningeal vessels.

Disentangling the two candidate triggers of that activation, hypoxia and reduced barometric pressure, remains difficult in a field design, and the authors are careful on this point. Animal experiments have shown that lowering atmospheric pressure by as little as 40 hectopascals increases firing in neurons of the spinal trigeminal nucleus, particularly those with corneal afferents, and human volunteers exposed to modest pressure drops in a climate chamber have reported head compression and mild-to-moderate headache. Meanwhile, chamber studies of pure normobaric hypoxia have induced headache in roughly 80 percent of healthy volunteers and elevated plasma CGRP in migraine patients. Because tear fluid CGRP did not rise uniformly across the expedition and did not track oxygen saturation, the new data hint that hypoxia by itself may be insufficient, and that the interplay of low pressure and low oxygen, possibly amplified in susceptible individuals, is what ignites the trigeminovascular system.

The study’s limitations are real and acknowledged by its authors. Thirteen completers is a small sample, nearly half the original cohort was excluded, tear fluid CGRP has not been formally validated against plasma or cerebrospinal fluid concentrations, and an observational design cannot establish whether the neuropeptide rise precedes the pain or merely accompanies it. Even so, the implications are tantalizing. If CGRP release genuinely drives altitude headache, then the CGRP-targeted monoclonal antibodies and small-molecule antagonists that have revolutionized migraine care might, in principle, be repurposed as prophylaxis for mountaineers, an idea the authors say deserves interventional study. And if tear fluid proves to be a reliable surrogate medium, field researchers could gain a practical, needle-free biomarker for headache severity in some of the most remote environments on Earth, from Himalayan base camps to aerospace settings, where the biology of low pressure and low oxygen has long outpaced our ability to measure it.

Subject of Research: The role of the neuropeptide CGRP in high-altitude headache and migraine-like headache during hypobaric hypoxia

Article Title: The Role of Calcitonin Gene‐Related Peptide in High‐Altitude Headache: A Prospective Field Study

Article References: Schniepp, R., Karrasch, L., Breitenstein, H., Straube, A., & Kamm, K. (2026). The Role of Calcitonin Gene‐Related Peptide in High‐Altitude Headache: A Prospective Field Study. Annals of Clinical and Translational Neurology, 13(10), 2046-2056. https://doi.org/10.1002/acn3.70374

Image Credits: AI Generated

DOI: 10.1002/acn3.70374

Keywords: high-altitude headache, CGRP, migraine, hypobaric hypoxia, trigeminovascular system, tear fluid biomarker, acute mountain sickness, transcranial duplex sonography, neuropeptides, Alps expedition, headache disorders, neurology

A new real-world study published in the Journal of Neurology by Alessia Bellotti of the Neurocenter of Southern Switzerland and colleagues now offers some of the most direct long-term evidence to date. Drawing on a prospective registry of migraine patients treated at a tertiary Headache Centre, the team identified every patient treated with CGRP pathway inhibitors who also carried a documented history of ischemic stroke, transient cerebral ischemic attack, or ischemic heart disease. Out of 420 consecutive patients in the registry, 17 individuals, roughly 4 percent, met these criteria and formed the study cohort. The number is small, but the clinical stakes are not, because each of these patients represents the exact scenario in which prescribing decisions have historically been made with the least data and the greatest uncertainty.

The biology behind the concern is worth unpacking. CGRP is not exclusively a migraine molecule; it is a potent vasodilator and neuropeptide distributed throughout the peripheral and central nervous systems, including the cerebral and coronary vasculature. Under physiological conditions it contributes to the regulation of vascular tone, and experimental work has suggested that CGRP may even play a protective role during cerebral ischemia and reperfusion injury. Blocking this pathway with a monoclonal antibody or a receptor antagonist could, in theory, blunt these protective mechanisms, particularly in vessels already compromised by atherosclerosis or prior infarction. This theoretical risk is amplified in patients whose brains have already demonstrated vulnerability to ischemia, since recurrent stroke carries a substantial cumulative risk, and cardiovascular guidelines emphasize aggressive secondary prevention in exactly this group.

Epidemiology deepens the dilemma rather than resolving it. Large prospective cohort studies have shown that migraine, particularly migraine with aura, is associated with an elevated risk of ischemic stroke in middle-aged and elderly populations, and neuroimaging research has linked migraine to deep white matter lesions and subclinical posterior circulation infarcts. Genetic studies reinforce the connection between migraine and stroke biology. In other words, the migraine patients most likely to have suffered a prior vascular event are not an incidental subgroup; they are the population in whom the migraine-vascular relationship is most pronounced. Denying them the most effective preventive therapies available would leave them exposed to the disabling consequences of chronic migraine, while prescribing without safety data would constitute an uncontrolled experiment. The Swiss registry study was designed to begin filling precisely this evidentiary gap.

The cohort itself reflects the clinical reality of severe, treatment-resistant migraine. The 17 patients had a median age of 54.5 years, 76 percent were women, and 82 percent suffered from chronic migraine, the most disabling form of the disorder, defined by headache on 15 or more days per month. The group accumulated a total of 31 patient-years of exposure to CGRP pathway inhibitors, with individual follow-up extending up to five years. Importantly, the median interval between the original ischemic event and the start of CGRP-targeted treatment was 5.0 years, with an interquartile range of 4.5 years, meaning that most patients were not treated in the immediate aftermath of a stroke or cardiac event but at a point when their vascular disease had been medically stabilized.

The efficacy findings were striking. Thirteen of the 17 patients, 76 percent, achieved a reduction of at least 50 percent in their monthly migraine days, a threshold widely regarded as a clinically meaningful response. Among the 14 patients with chronic migraine, 10 reached this benchmark, and remarkably, all three patients with episodic migraine did so as well. These response rates compare favorably with those reported in broader real-world cohorts of migraine patients without vascular comorbidity, suggesting that a history of stroke or ischemic heart disease does not blunt the therapeutic benefit of CGRP blockade. For patients who had often exhausted multiple conventional preventives, the magnitude of improvement represents a transformation in daily functioning and quality of life.

On the safety side, the results were equally notable for what the investigators did not find. Across the entire follow-up period, no recurrent cerebrovascular events were observed, and no worsening of underlying cardiac disease was documented. In a subset of patients, serial neuroimaging was performed, and dedicated neuroradiological assessment revealed no new ischemic lesions. This combination of clinical and radiological surveillance is significant, because silent ischemic lesions can occur without overt symptoms, and their absence on imaging provides a more sensitive measure of cerebrovascular integrity than clinical history alone. The involvement of a dedicated neuroradiologist, who assessed ischemic lesions using specialized software, adds technical rigor to the imaging component of the study.

The authors are careful, and rightly so, to frame these findings as exploratory and hypothesis-generating rather than definitive. Seventeen patients and 31 patient-years of exposure cannot exclude a modest increase in vascular risk, and the absence of a control group means that the background rate of recurrent events in comparable untreated patients cannot be formally compared. Registry data from a single tertiary center may also be subject to selection effects, since patients considered for CGRP therapy after a stroke are likely to have been judged clinically stable by their treating physicians. Nevertheless, the study aligns with a growing body of real-world evidence, including multicenter safety evaluations of CGRP-targeting antibodies in patients with comorbidities excluded from trials, analyses of cardiovascular safety in older adults, and large pharmacoepidemiological studies examining cardiovascular events among migraine patients exposed to these drugs.

The report also touches on one of the most debated corner cases in the field: CADASIL, a hereditary small-vessel disease characterized by subcortical infarcts and leukoencephalopathy, in which CGRP has been hypothesized to play a protective vascular role. The Swiss registry included a CADASIL case among its patients, and prior case reports have described long-term treatment with the receptor antagonist erenumab in CADASIL without apparent harm, even as commentators have warned about the potential danger of blocking CGRP in such patients. By contributing longitudinal, imaging-verified data from this rare and theoretically highest-risk scenario, the study adds a valuable data point to an ongoing conversation about whether CGRP inhibition is safe in small-vessel cerebrovascular disease.

For clinicians, the practical message is one of cautious reassurance. In patients with prior ischemic stroke, transient ischemic attack, or ischemic heart disease whose vascular disease is stable, CGRP pathway inhibitors appear, on current real-world evidence, to deliver their expected efficacy without detectable clinical or radiological ischemic consequences over follow-up periods of up to five years. This does not eliminate the need for individualized risk assessment, coordination with vascular specialists, and continued surveillance, particularly in the early years after an ischemic event, where the evidence remains sparse. But it does shift the default conversation from whether these drugs can be used at all to how best to monitor them. For the large population of migraine patients living with the dual burden of severe headache and established vascular disease, that shift, however incremental, is genuinely good news, and it underscores the value of prospective registries in answering the safety questions that randomized trials were never designed to address.

Subject of Research: Long-term cerebrovascular and cardiovascular safety of CGRP pathway inhibitors in migraine patients with prior ischemic events

Article Title: Long-term safety of CGRP pathway inhibitors in migraine patients with prior cerebrovascular or cardiovascular disease

Article References: Long-term safety of CGRP pathway inhibitors in migraine patients with prior cerebrovascular or cardiovascular disease. (n.d.). https://doi.org/10.1007/s00415-026-14099-z

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14099-z

Keywords: CGRP, migraine, stroke, ischemic heart disease, monoclonal antibodies, cerebrovascular safety, CADASIL, real-world registry, neuroimaging, preventive treatment, transient ischemic attack, Journal of Neurology

The logic behind the approach builds on a decade of epilepsy gene therapy. Most experimental genetic treatments for seizures work by boosting the potassium conductance of neurons, effectively adding brake pedals to cells that fire too readily. Adeno-associated virus vectors, the workhorses of modern neurological gene therapy, are used to smuggle engineered ion channel genes into a circumscribed patch of brain tissue, where they render hyperexcitable neurons less likely to ignite pathological activity. Because seizures and spreading depolarization frequently co-occur, the Moscow group, led by Evgeny Nikitin and Lyudmila Vinogradova, asked a question that had not been systematically addressed: what happens to spreading depolarization when you give neurons extra potassium conductance?

The channel they chose was KCa3.1, encoded by the gene KCNN4. Unlike voltage-gated potassium channels, KCa3.1 opens in response to intracellular calcium, which surges whenever a neuron fires vigorously. This makes the channel a self-regulating safety valve: the harder a cell works, the more the channel opens, letting potassium ions flow out and pulling the membrane potential back toward rest. Earlier work by the same team had shown that overexpressing KCNN4 in principal neurons produces an anti-seizure effect without degrading the cells’ ability to encode information, a crucial consideration for any therapy that must leave normal brain function intact. Whether the same manipulation would influence the massive, synchronized ionic collapse of spreading depolarization was an open question.

To find out, the researchers injected an AAV vector carrying KCNN4 into the neocortex of mice and then attacked the problem from three technical directions. Patch-clamp electrophysiology allowed them to record the membrane potential of individual neurons as a depolarization wave swept past. Functional imaging in acute brain slices, using voltage- and calcium-sensitive indicators, revealed how the wave propagated through the cortical network. And direct-current-coupled field potential recordings captured the full signature of spreading depolarization in vivo, including in awake, non-anesthetized animals, a demanding preparation that avoids the confounding effects of anesthetics on cortical excitability.

The results were striking. KCNN4 expression reduced the amplitude of the spreading depolarization several-fold, an effect documented both in slices and in the intact cortex of freely moving mice. The wave also traveled more slowly through treated tissue, as measured by the timing of its arrival at recording sites in the slices. Slower propagation matters clinically: the damage inflicted by spreading depolarization after stroke or traumatic brain injury is thought to scale with the depth and duration of the ionic disruption, so a wave that is smaller and slower should, in principle, be less injurious. In patients with malignant stroke or decompressive craniectomy, spreading depolarizations detected with subdural electrodes are associated with worse outcomes, making amplitude and propagation speed attractive therapeutic targets.

The gene therapy also reshaped the aftermath of the wave. Spreading depolarization imposes a period of profound neuronal silencing, during which epileptiform activity is temporarily abolished. Paradoxically, in the KCNN4-treated slices this suppression ended sooner, with seizure-like events reappearing earlier than in control tissue. The finding highlights a subtle and clinically important trade-off. Some evidence suggests that spreading depolarization itself can act as an innate antiseizure mechanism, terminating seizures by short-circuiting electrical propagation across the cortex. A therapy that shrinks the depolarization wave might therefore, in some circumstances, shorten the very silencing that ends a seizure. The authors flag this as a side effect that any potassium-conductance-enhancing gene therapy for epilepsy will need to weigh.

Delving into the mechanism, the team documented a calcium rebound that follows spreading depolarization when epileptiform activity resumes. As neurons recover and begin firing again, intracellular calcium climbs steeply, and this rebound can feed back into the intensity of the recovered activity. In KCNN4-expressing neurons, the channel’s calcium sensitivity turns this rebound to advantage: the rising calcium opens the overexpressed KCa3.1 channels, which generate a potassium-mediated afterhyperpolarization that counterbalances the depolarizing drive. In effect, the therapy converts a vicious cycle, in which calcium influx amplifies excitability, into a negative feedback loop that restrains it. This cell-autonomous quality, where each neuron polices its own excitability, distinguishes the approach from drugs that act globally and indiscriminately.

The technical execution relied on a mature toolkit. AAV vectors have become the dominant platform for nervous system gene therapy because they are relatively safe, transduce neurons efficiently, and support long-term expression. The team’s vector design and cloning were performed in-house, and the imaging data were processed with supervised calcium event detection tools developed by the group. The in vivo experiments in awake animals are particularly notable, since spreading depolarization amplitude and threshold can be altered by anesthesia, and recordings from non-anesthetized mice provide the most physiologically relevant readout of how the therapy would behave in a clinical setting.

The broader significance lies in the intersection of two therapeutic frontiers. Gene therapy for epilepsy is advancing rapidly, with engineered potassium channels, optogenetic tools, and on-demand dynorphin-based systems all showing efficacy in rodent models, and at least one company has raised substantial funding to develop a single-dose gene therapy for focal refractory epilepsy. Spreading depolarization, meanwhile, has emerged as a therapeutic target in its own right, with ketamine trials in acute brain injury aiming to suppress the waves pharmacologically. The new study connects these threads, demonstrating that a single genetic manipulation can simultaneously dampen seizures and attenuate spreading depolarization, while also revealing the unexpected interaction between the two phenomena.

Caveats remain before any translation to patients. The work is a proof of principle in rodents, and the authors themselves note that reducing spreading depolarization via increased potassium conductance may carry the paradoxical risk of prolonging seizure activity by removing a natural braking mechanism. The dosing of channel expression, the durability of the effect, and the behavior of the therapy in injury models of stroke and trauma all await further study. Still, the demonstration that a targeted viral gene delivery can measurably shrink one of the brain’s most violent electrical events opens a concrete path toward treating disorders, from migraine to stroke, that are complicated by spreading depolarization, using nothing more than the neurons’ own molecular machinery.

Subject of Research: Viral gene therapy targeting spreading depolarization via KCa3.1 potassium channel expression

Article Title: Local targeted suppression of neocortical spreading depolarization amplitude by viral expression of KCa3.1 channels

Article References: Oblasov, I. A., Smirnova, M. P., Borodinova, A. A., Zuzina, A. B., Smirnov, I. A., Balaban, P. M., Vinogradova, L. V., & Nikitin, E. S. (2026). Local targeted suppression of neocortical spreading depolarization amplitude by viral expression of KCa3.1 channels. Gene Therapy. https://doi.org/10.1038/s41434-026-00645-x

Image Credits: AI Generated

DOI: 10.1038/s41434-026-00645-x

Keywords: spreading depolarization, gene therapy, KCa3.1, KCNN4, adeno-associated virus, epilepsy, migraine, stroke, potassium channels, neocortex, electrophysiology, afterhyperpolarization

The Innovative Project Award provides $200,000 over two years and is deliberately designed to back high-risk, high-reward science. Eligible projects spanned the full breadth of biomedical inquiry, from basic laboratory studies of cells and molecules to clinical investigations and population health research, and applicants could propose work across the entire human lifespan, from children and adolescents through middle age and late life. The prioritization of innovation over incremental safety reflects a conscious strategy by both societies: rather than extending established research programs, they wanted to seed ideas that conventional funding mechanisms might consider too speculative, but that could open entirely new avenues for preventing stroke and heart disease in people living with chronic headache disorders.

This year’s co-funded award goes to Juliana Navia Pelaez, Ph.D., an assistant professor at St. Louis University School of Medicine in St. Louis, Missouri, for a project titled “Neurogenic Priming of Perivascular Macrophages by Migraine-Associated Peptides Increases Stroke Risk.” Her work targets a question that has long puzzled clinicians: why some people who suffer from migraine face a higher risk of stroke. Researchers have traditionally concentrated on the blood vessels themselves, since during a migraine attack these vessels may tighten, swell, or alter the way blood moves through them. But attention is now shifting toward another, less obvious player — the brain’s own resident immune cells, which stand guard along the vessels and help protect neural tissue from injury.

Pelaez’s central hypothesis is that repeated migraine attacks may push these vascular immune cells into a state of chronic overactivation. “If migraines happen over and over, these immune cells might stay ‘on’ for too long. When this happens, they might accidentally make the blood vessels weaker,” Pelaez said. “If the vessels get weaker, the brain might have a harder time protecting itself from a stroke.” In practical terms, the project will map which signals released during a migraine activate these brain immune cells, and then compare how the cells respond to a subsequent stroke in animals that have experienced migraine-like events versus those that have not. The comparison is designed to isolate the specific contribution of migraine biology to stroke vulnerability, rather than attributing everything to shared risk factors such as hypertension or smoking.

The translational implications could be considerable. “If our idea is right,” Pelaez added, “this could help scientists find new ways to prevent strokes in people with chronic migraine, maybe by calming these overactive brain cells or blocking the signals that bother them.” Such a strategy would represent a fundamentally different approach to stroke prevention in this population. Instead of managing vascular risk factors after the fact, clinicians might one day intervene directly on the neuroimmune signaling cascade that links repeated migraine attacks to cumulative vessel damage — a possibility that could reshape how neurologists and cardiologists jointly manage patients with frequent or chronic migraine.

The Heart Association’s three additional awards extend the same investigative ambition across distinct mechanistic frontiers. The first goes to Andrea M. Harriott, M.D., Ph.D., an assistant professor in neurology at Massachusetts General Hospital in Boston, for a study titled “The Impact Of Cortical Spreading Depolarizations On Endothelial Phenotype, Neovascularization, and Collateral Remodeling.” Migraine with aura has long been epidemiologically linked to stroke and heart attack, and earlier thinking held that this association might simply reflect an elevated burden of conventional risk factors among people with aura. Harriott’s project will test a more direct possibility: that the long-term exposure to the mechanisms underlying migraine aura — cortical spreading depolarizations, waves of altered electrical and metabolic activity that sweep across the brain — causes lasting structural and functional harm to cerebral blood vessels. Her team will examine protein-level changes in the cells lining vessel walls, the formation of new blood vessels, and the remodeling of collateral circulation that the brain relies on when its primary supply routes are compromised.

The second award supports Matthew T. Bender, M.D., an associate professor at the University of Rochester in Rochester, New York, whose project, “Defining The Glymphatic-Hemodynamic Axis In IIH: A Novel Multi-Scale Quantitative MRI Framework,” addresses idiopathic intracranial hypertension, or IIH. This headache disorder disproportionately affects overweight women of childbearing age, and clinicians believe it arises from elevated pressure inside the skull driven by excess cerebrospinal fluid. Recent evidence, however, suggests the disorder may also involve dysfunction of the brain’s waste clearance network, known as the glymphatic system. Bender’s team will develop a new magnetic resonance imaging framework capable of visualizing both the glymphatic system and cerebral blood flow without contrast dye or invasive procedures. By scanning IIH patients before and after venous stenting — a procedure that opens narrowed veins draining the brain — the researchers hope to determine how restoring venous outflow affects waste clearance and hemodynamics, potentially establishing imaging markers that could guide treatment decisions.

The third award funds Neil Dani, Ph.D., an assistant professor at Vanderbilt University in Nashville, Tennessee, for “Illuminating Nociceptive And Analgesic Mechanisms Of Choroid Plexus In Migraine And Obesity Models.” Dani’s work responds to the rising prevalence of obesity-related migraine, a clinically important overlap given that both conditions share inflammatory signaling pathways. His focus is the choroid plexus, a small structure inside the brain’s ventricles that produces cerebrospinal fluid and acts as a highly regulated interface, or gate, between the body and the central nervous system. The working hypothesis is that inflammatory signals generated in the body during obesity may travel through the cerebrospinal fluid via the choroid plexus, sensitizing pain circuits and increasing migraine frequency or severity. The project will characterize inflammation patterns in this structure, identify cellular rewiring and immune signaling changes associated with obesity and migraine, and test whether clinically approved drugs — including acetazolamide, a long-standing medication already used in related contexts — can reduce both swelling and pain signaling in experimental models.

Taken together, the four projects sketch a research landscape in which headache disorders and vascular medicine are no longer treated as separate silos. Each award interrogates a different node of the heart-brain axis: immune cells that patrol cerebral vessels, the electrical storms of migraine aura and their vascular aftermath, the interplay of intracranial pressure and brain waste clearance, and the inflammatory crosstalk between metabolism, body-wide immune signaling, and pain. The funders emphasize that these efforts demonstrate the shared commitment of the American Headache Society and the American Heart Association to advancing brain health research, and the co-funding structure itself may prove as influential as the science it supports, encouraging cross-disciplinary training, shared patient cohorts, and unified endpoints across neurology and cardiology.

The initiative also sits within a far larger funding tradition. Supporting scientific research and discovery through programs of this kind is a cornerstone of the century-old American Heart Association’s lifesaving mission. Since 1949, the Association has invested more than $6.3 billion in cardiovascular, cerebrovascular, and brain health research, making it the single largest non-profit, non-governmental supporter of heart and brain health research in the United States. Officials note that knowledge generated through this funding continues to save lives and directly affect millions of people across the country and around the world. For the millions who live with migraine and other headache disorders — and for the clinicians who care for them — the new awards offer something more immediate than long-term promise: a concrete, funded research agenda that treats the pounding in the head and the health of the heart and brain’s vessels as inseparable parts of the same biological story.

Subject of Research: Funded research projects investigating the links between migraine, headache disorders, and cardiovascular and cerebrovascular health

Article Title: New scientific research projects study heart/brain connection to migraines, headaches

Article References: New scientific research projects study heart/brain connection to migraines, headaches. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: migraine, stroke, American Heart Association, American Headache Society, cerebrovascular health, cortical spreading depolarization, idiopathic intracranial hypertension, glymphatic system, choroid plexus, perivascular macrophages, obesity-related migraine, research funding

The review, led by Qing Huang and colleagues, synthesizes epidemiological data, neuroimaging findings, electrophysiological studies, and treatment reports to build an integrated framework for the syndrome. Its central claim is provocative: the anxiety, depression, depersonalization, fatigue, and sleep disturbances that so often accompany visual snow may not simply be psychological reactions to a chronic and distressing symptom. Instead, they may be intrinsic expressions of the same underlying neurobiology, reflecting dysfunction in the shared circuits that govern perception, emotion regulation, and salience attribution. This reframing has significant implications for how clinicians diagnose, investigate, and ultimately treat the disorder.

Epidemiologically, visual snow syndrome appears to be far from rare. Cross-sectional studies conducted in Italy, the United Kingdom, and Russia have estimated prevalence at between 0.7 and 4.4 percent, using symptom-based screening questionnaires followed by clinical validation. An online survey found that 41.9 percent of respondents had experienced visual snow phenomena at some point, yet only 4.49 percent met the full diagnostic criteria of the International Classification of Headache Disorders, third edition. Most affected individuals screened in prevalence studies had never received a formal diagnosis before enrollment, underscoring how frequently the condition escapes clinical recognition. Cohorts typically show a female predominance and a mean age of roughly 25 to 30 years, although one large study of more than 1,100 patients found no significant sex difference and a mean age of 29.

Onset patterns are strikingly variable. Reported proportions of childhood-onset cases, in which symptoms have been present for as long as the patient can remember, range from 17.2 percent in a hospital-based outpatient study to 89.6 percent in an online survey, with two large cohorts suggesting approximately 40 percent. The review cautions that this phrase should not be equated with a truly congenital condition, although the data raise the possibility of a genetically predisposed congenital subtype whose true prevalence remains unknown. In other patients, onset follows a precipitating event: 42.3 percent of patients in one study reported a triggering event or associated comorbidity. Migraine is the most common, affecting roughly 50 to 70 percent of patients, and the likelihood of developing the syndrome is significantly elevated among people with migraine. Case reports implicate occipital ischemic stroke, hallucinogen persisting perception disorder associated with substances such as LSD and delta-8-tetrahydrocannabinol, selective serotonin reuptake inhibitor exposure, mild traumatic brain injury, infection, idiopathic intracranial hypertension, and ocular abnormalities. The emerging picture is of a disorder triggered by multiple environmental or pathological factors in genetically susceptible individuals.

The mechanistic evidence reviewed by the authors is where the network concept gains its force. Ultra-high-field 7 Tesla structural MRI has revealed that, despite the absence of gross morphometric abnormalities, patients show reduced T1 values following a clear caudorostral gradient, most pronounced in the occipital cortex and diminishing toward parietal, temporal, and prefrontal regions. Significant T1 reductions across multiple thalamic nuclei suggest alterations in neuronal density, membrane integrity, or microstructural organization, while voxel-based morphometry has documented increased gray matter volume at the right lingual gyrus–fusiform gyrus junction and in temporal and limbic lobes, alongside reduced volume in the superior temporal gyrus. Together, these findings map a distributed visual–thalamic–limbic architecture rather than a single lesioned locus.

Functional studies reinforce this distributed view. Magnetoencephalography has demonstrated increased gamma-band power in the primary visual cortex, a signature of cortical hyperexcitability, together with reduced alpha-phase-to-gamma-amplitude coupling, indicating impaired top-down inhibitory modulation from higher-order visual areas. Resting-state EEG shows reduced alpha-band power spectral density in the parietotemporal region, corresponding to secondary visual cortex dysfunction, and abnormally enhanced activity-dependent neuroplasticity has also been reported. Positron emission tomography reveals hypermetabolism in the right extrastriate cortex accompanied by hypometabolism in temporoparietal regions involved in auditory processing and attentional control. Functional MRI demonstrates abnormal connectivity within the visual network and disrupted connections involving the thalamus, basal ganglia, default mode network, and salience-attention systems, both at rest and during stimulation. EEG microstate analyses add evidence of unstable large-scale network dynamics, with reduced microstate duration and amplitude and abnormal transitions among auditory–visual, visual, and salience-related states. In this model, patients cannot effectively suppress internally generated visual noise, allowing it to enter conscious awareness as continuous static.

Crucially, the same circuitry offers a bridge to the psychiatric dimension. Neuroimaging has identified increased gray matter volume in bilateral limbic structures, including the anterior cingulate cortex, insula, and prefrontal cortex, along with hypometabolism in the hippocampal–parahippocampal region. Reduced parahippocampal–occipital connectivity correlates significantly with subjective distress, suggesting disruption of a perception–emotion–inhibition loop. Receptor-enriched connectivity analyses point to abnormalities in glutamatergic and serotonergic pathways within the anterior cingulate, insula, orbitofrontal cortex, and visual association areas. Notably, psychiatric symptom severity does not differ between childhood-onset and later-onset patients, and longitudinal studies show that anxiety and depressive symptoms remain stable over time, patterns more consistent with shared neurobiology than with purely reactive distress. Familial aggregation adds a genetic dimension: 2.4 to 10 percent of first-degree relatives are affected, and migraine prevalence among relatives ranges from 9.4 to 56 percent, hinting at shared vulnerability, though no genome-wide association or linkage studies have yet been performed.

The clinical burden is substantial. Depressive symptoms affect between 14.1 and 53 percent of patients depending on the instrument and design, while anxiety symptoms range from 15.4 to 49 percent; longitudinal assessments found lifetime rates of 41.4 percent for depression and 44.8 percent for anxiety, and symptom severity correlates with visual symptom severity. Approximately 45 percent of patients experience depersonalization, with a quarter reaching clinical threshold. Sleep is frequently disrupted, with 44.8 percent reporting difficulty initiating sleep due to visual interference in darkness, and 49.6 percent meeting criteria for clinically significant fatigue. Quality of life is markedly impaired across mental health, social functioning, and role-emotional domains, and recent work shows that self-efficacy and quality of life sequentially mediate the relationship between symptom burden and adverse outcomes including depression and suicidal ideation, identifying psychosocial mechanisms as actionable intervention targets.

Treatment remains the weakest link. Pharmacological options are largely empirical and modestly effective: lamotrigine produced partial improvement in 19.2 percent of patients in one study with no complete remissions and adverse reactions in half of users, while topiramate response rates range from 15.4 to 28.5 percent. A survey of 400 patients found that antidepressants, antiepileptic drugs, antibiotics, and benzodiazepines were generally ineffective and often poorly tolerated. By contrast, non-pharmacological approaches show encouraging preliminary signals. Tinted lenses, particularly yellow and blue spectral filters, reduce the intensity, duration, and frequency of visual snow in 80 to 92 percent of individuals and improve palinopsia and photophobia by roughly 50 percent on average. Repetitive transcranial magnetic stimulation targeting the visual cortex or bilateral lingual gyri has shown favorable safety and preliminary efficacy, and prolonged exposure to high-contrast dynamic visual noise can reduce or temporarily eliminate symptoms. Mindfulness-based cognitive therapy has demonstrated dual benefits for visual symptoms and psychological distress, plausibly by modulating visual network connectivity through enhanced attentional flexibility and non-reactive awareness. Patients also report that darkness, bright light, stress, alcohol, sleep deprivation, and prolonged screen exposure worsen symptoms, while adequate sleep, stress reduction, meditation, and regular exercise help.

The review’s authors are careful to note that much of the current evidence derives from cross-sectional, retrospective, or uncontrolled studies, so causal relationships among visual symptoms, network dysfunction, and psychiatric manifestations must be interpreted cautiously. Yet the convergence of structural, functional, electrophysiological, and neurochemical findings on a single integrated model is difficult to ignore. They call for multidisciplinary research integrating neurology, psychiatry, neuroimaging, electrophysiology, and genetics, including Mendelian randomization, polygenic risk scoring, and multi-omics approaches, to identify biomarkers linking symptom dimensions to specific network and molecular alterations. For a condition that affects as many as one in twenty-five people by some estimates yet remains routinely missed, recognizing visual snow syndrome as a genuine neuropsychiatric network disorder may be the first step toward precision diagnosis and, eventually, effective therapy.

Subject of Research: Visual snow syndrome as a neuropsychiatric network disorder involving visual cortical hyperexcitability, thalamocortical dysrhythmia, and limbic dysfunction

Article Title: Visual snow syndrome as a neuropsychiatric network disorder: clinical features, mechanisms, and therapeutic perspectives

Article References: Huang, Q., Wang, J., Zhao, L., Yu, X., Wang, W., Wang, Z., & Liu, Y. (2026). Visual snow syndrome as a neuropsychiatric network disorder: clinical features, mechanisms, and therapeutic perspectives. Journal of Neurology, 273(10), Article 610. https://doi.org/10.1007/s00415-026-14137-w

Image Credits: AI Generated

DOI: 10.1007/s00415-026-14137-w

Keywords: visual snow syndrome, neuropsychiatric disorders, thalamocortical dysrhythmia, functional connectivity, migraine, depersonalization, neuroimaging, transcranial magnetic stimulation, tinted lenses, mindfulness-based cognitive therapy, anxiety, depression